Initial Experience of Sodium-Glucose Cotransporter 2 Inhibitors in Adolescents with Heart Failure Due to Muscular Dystrophy

Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are novel agents in the management of adult heart failure (HF) with proven mortality benefit in large, randomized control trials. Now the standard of care in adult guideline-directed medical therapy (GDMT), SGLT2i are increasingly being used off-label in pediatric patients. Patients with Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), progressive X-linked myopathies that primarily affect males in their early teenage years, can develop HF secondary to dilated cardiomyopathy (DCM).

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , E. Kramer, D. Weber, H. Ahmed, M.J. O'Connor, J.B. Edelson, J.J. Edwards, K.Y. Lin, J.W. Rossano, C.A. Wittlieb-Weber, J.H. Berger Source Type: research